Handelsbanken Fonder
AVDL

Handelsbanken Fonder’s Avadel Pharmaceuticals AVDL Stock Holding History

Handelsbanken Fonder’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-36,400
Closed -$784K – 1498
2025
Q4 		$784K Buy
36,400
+2,300
+7% +$44.7K ﹤0.01% 1151
2025
Q3 		$521K Hold
34,100
– – ﹤0.01% 1245
2025
Q2 		$302K Buy
+34,100
New +$300K ﹤0.01% 1423

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Handelsbanken Fonder's AVDL Position: Q1 2026 in Review

Handelsbanken Fonder sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 36,400 shares — an estimated $784K sold.

Handelsbanken Fonder first reported a position in AVDL in Q2 2025 and held it in 3 quarters. The position peaked at $784K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Handelsbanken Fonder reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Handelsbanken Fonder sold 36,400 Avadel Pharmaceuticals shares in Q1 2026, an estimated $784K.
  • Handelsbanken Fonder first reported a position in Avadel Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Handelsbanken Fonder's Avadel Pharmaceuticals position peaked at $784K in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Handelsbanken Fonder's 13F filing for Q1 2026, filed 28 Apr 2026.